Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833495 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
A Phase 2 study of Allergic Conjunctivitis, sponsored by Fovea Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
- 1
- Study location
NCT00833495 is a Phase 2 study of Allergic Conjunctivitis that has completed, run by Fovea Pharmaceuticals. The registered enrollment target is 155 participants, above the 127-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (22% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00833495, a Phase 2 study of Allergic Conjunctivitis, has completed, sponsored by Fovea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2 study that will consist of 3 visits during a 3 week period conducted at up to 5 sites. The purpose of this study is to determine how effective the combination of Pred Mild® and FOV1101-00 is compared to either Pred Forte® alone or to vehicle alone in the prevention of eye allergies. Study subjects will be randomized to one of the following: * FOV1101-00 concentration 1 and Pred Mild® * FOV1101-00 concentration 2 and Pred Mild® * Vehicle of FOV1101-00 and Pred Forte® * Vehicle of FOV1101-00 and Vehicle of FOV1101-00
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prednisolone Acetate 0.12% (Pred Mild®)
- DRUG FOV1101-00
- DRUG Prednisolone Acetate 1% (Pred Forte®)
Study Locations (1)
Massachusetts
- Ora - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833495
The ClinicalTrials.gov registry entry for NCT00833495 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 127-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (22% higher). The listed sponsor is Fovea Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00833495 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00833495 about?
NCT00833495 is a clinical study titled "Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation". This is a phase 2 study that will consist of 3 visits during a 3 week period conducted at up to 5 sites. The purpose of this study is to determine how effective the combination of Pred Mild® and FOV1101-00 is compared to either Pred Forte® alone or to vehicle alone in the prevention of eye allergies...
What is the current status of trial NCT00833495?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2009-01. Estimated completion is 2009-03.
What conditions does trial NCT00833495 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT00833495?
The interventions under investigation include: Placebo (DRUG), Prednisolone Acetate 0.12% (Pred Mild®) (DRUG), FOV1101-00 (DRUG), Prednisolone Acetate 1% (Pred Forte®) (DRUG).
Who is sponsoring clinical trial NCT00833495?
This trial is sponsored by Fovea Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00833495 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
RECRUITING · Phase 2
-
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 2
-
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
COMPLETED · Phase 2
-
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
COMPLETED · Phase 2
-
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.